Y-mAbs Therapeutics (YMAB) Earnings Date, Estimates & Call Transcripts $8.78 -0.75 (-7.87%) (As of 05:27 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Y-mAbs Therapeutics Latest Earnings SummaryActual EPS (Nov. 8) -$0.16 Missed By -$0.02 Consensus EPS (Nov. 8) -$0.14 Y-mAbs Therapeutics released Q3 2024 earnings on November 8, 2024, reporting an EPS of -$0.16, which missed the consensus estimate of -$0.14 by $0.02. Quarterly revenue was reported to be $18.46 million, below the consensus estimate of $23.38 million. With a trailing EPS of -$0.54, Y-mAbs Therapeutics' earnings are expected to grow next year, from ($0.66) to ($0.56) per share. Conference CallConference Call TranscriptPowered by Get Y-mAbs Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataYMAB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.YMAB Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Y-mAbs Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.22-$0.11-$0.17Q2 20242-$0.14-$0.11-$0.13Q3 20242-$0.15-$0.09-$0.12Q4 20243-$0.23-$0.06-$0.15FY 20249-$0.74-$0.37-$0.56Q1 20252-$0.22-$0.16-$0.19Q2 20253-$0.22-$0.06-$0.14Q3 20253-$0.21-$0.07-$0.14Q4 20253-$0.29-$0.07-$0.17FY 202511($0.94)($0.36)($0.65) Y-mAbs Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/8/2024Q3 2024-$0.14-$0.16 -$0.02-$0.16$23.38M$18.46M8/12/2024Q2 2024-$0.13-$0.21 -$0.08-$0.21$23.09M$22.80M5/7/2024Q1 2024-$0.12-$0.15 -$0.03-$0.15$22.06M$19.93M2/29/2024Q4 2023-$0.19-$0.02+$0.17-$0.02$21.72M$23.36M11/13/2023Q3 2023-$0.16-$0.18 -$0.02-$0.18$20.56M$20.45M8/10/2023Q2 2023-$0.24-$0.14+$0.10-$0.14$19.04M$20.75M Get the Latest News and Ratings for YMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/8/2023Q1 2023-$0.31-$0.15+$0.16-$0.15$15.55M$20.30M3/31/2023Q4 2022-$0.44$0.03+$0.47$0.03$20.35M$31.45M Y-mAbs Therapeutics Earnings - Frequently Asked Questions When did Y-mAbs Therapeutics announce their last quarterly earnings? Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earning data on Friday, November 8, 2024. Learn more on YMAB's earnings history. What guidance has Y-mAbs Therapeutics issued on next quarter's earnings? Y-mAbs Therapeutics issued an update on its FY 2024 earnings guidance on Friday, November, 8th. The company issued revenue guidance of $87.0 million-$95.0 million, compared to the consensus revenue estimate of $91.7 million. Did Y-mAbs Therapeutics beat their earnings estimates last quarter? In the previous quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) missed the analysts' consensus estimate of ($0.14) by $0.02 with a reported earnings per share (EPS) of ($0.16). Learn more on analysts' earnings estimate vs. YMAB's actual earnings. How can I listen to Y-mAbs Therapeutics's earnings conference call? The conference call for Y-mAbs Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Y-mAbs Therapeutics's conference call transcript? The conference call transcript for Y-mAbs Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Y-mAbs Therapeutics generate each year? Y-mAbs Therapeutics (NASDAQ:YMAB) has a recorded annual revenue of $84.55 million. How much profit does Y-mAbs Therapeutics generate each year? Y-mAbs Therapeutics (NASDAQ:YMAB) has a recorded net income of -$21.43 million. YMAB has generated -$0.54 earnings per share over the last four quarters. What is Y-mAbs Therapeutics's EPS forecast for next year? Y-mAbs Therapeutics's earnings are expected to grow from ($0.66) per share to ($0.56) per share in the next year. More Earnings Resources from MarketBeat Related Companies Galapagos Earnings Xencor Earnings Arcutis Biotherapeutics Earnings Kiniksa Pharmaceuticals Earnings Nurix Therapeutics Earnings Immunocore Earnings Arcus Biosciences Earnings Ocular Therapeutix Earnings Intellia Therapeutics Earnings Travere Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] This page (NASDAQ:YMAB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
